4.5 Article

Prognostic factors, long-term survival, and outcome of cancer patients receiving chemotherapy in the intensive care unit

Journal

ANNALS OF HEMATOLOGY
Volume 93, Issue 10, Pages 1629-1636

Publisher

SPRINGER
DOI: 10.1007/s00277-014-2141-x

Keywords

Chemotherapy; Acute leukemia; Lymphoma; Cancer; Intensive care unit; Tumor lysis syndrome

Categories

Ask authors/readers for more resources

Prognostic factors and outcomes of cancer patients with acute organ failure receiving chemotherapy (CT) in the intensive care unit (ICU) are still incompletely described. We therefore retrospectively studied all patients who received CT in any ICU of our institution between October 2006 and November 2013. Fifty-six patients with hematologic (n = 49; 87.5 %) or solid (n = 7; 12.5 %) malignancies, of which 20 (36 %) were diagnosed in the ICU, were analyzed [m/f ratio, 33:23; median age, 47 years (IQR 32 to 62); Charlson Comorbidity Index (CCI), 3 (2 to 5); Simplified Acute Physiology Score II (SAPS II), 50 (39 to 61)]. The main reasons for admission were acute respiratory failure, acute kidney failure, and septic shock. Mechanical ventilation and vasopressors were employed in 34 patients (61 %) respectively, hemofiltration in 22 (39 %), and extracorporeal life support in 7 (13 %). Twenty-seven patients (48 %) received their first CT in the ICU. Intention of therapy was cure in 46 patients (82 %). Tumor lysis syndrome (TLS) developed in 20 patients (36 %). ICU and hospital survival was 75 and 59 %. Hospital survivors were significantly younger; had lower CCI, SAPS II, and TLS risk scores; presented less often with septic shock; were less likely to develop TLS; and received vasopressors, hemofiltration, and thrombocyte transfusions in lower proportions. After discharge, 88 % continued CT and 69 % of 1-year survivors were in complete remission. Probability of 1- and 2-year survival was 41 and 38 %, respectively. Conclusively, administration of CT in selected ICU cancer patients was feasible and associated with considerable long-term survival as well as long-term disease-free survival.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis

Roberta Zanotti, Massimiliano Bonifacio, Giuseppe Lucchini, Wolfgang R. Sperr, Luigi Scaffidi, Bjoern van Anrooij, Hanneke N. C. Oude Elberink, Julien Rossignol, Olivier Hermine, Aleksandra Gorska, Magdalena Lange, Emir Hadzijusufovic, Cornelius Miething, Sabine Muller, Cecelia Perkins, William Shomali, Chiara Elena, Anja Illerhaus, Mohamad Jawhar, Roberta Parente, Francesca Caroppo, Oleksii Solomianyi, Alexander Zink, Mattias Mattsson, Akif Selim Yavuz, Jens Panse, Judit Varkonyi, Michael Doubek, Vito Sabato, Christine Breynaert, Vladan Vucinic, Tanja Schug, Hans Hagglund, Friederike Wortmann, Knut Brockow, Irena Angelova-Fischer, Anna Belloni Fortina, Massimo Triggiani, Andreas Reiter, Karin Hartmann, Luca Malcovati, Jason Gotlib, Khalid Shoumariyeh, Marek Niedoszytko, Michel Arock, Hanneke C. Kluin-Nelemans, Patrizia Bonadonna, Peter Valent

Summary: Bone marrow mastocytosis (BMM) is a provisional variant of indolent systemic mastocytosis (ISM) defined by bone marrow involvement and absence of skin lesions in the current WHO classification. BMM patients were older, predominantly male, had lower tryptase levels, lower neoplastic mast cell burden, and a higher frequency of allergic reactions triggered mainly by Hymenoptera compared to typical ISM patients. The 10-year progression-free survival of BMM was higher than that of typical ISM, and specific risk factors for progression in BMM patients were identified.

LEUKEMIA (2022)

Article Oncology

Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

Christoph Kornauth, Tea Pemovska, Gregory Vladimer, Gunther Bayer, Michael Bergmann, Sandra Eder, Ruth Eichner, Martin Erl, Harald Esterbauer, Ruth Exner, Verena Felsleitner-Hauer, Maurizio Forte, Alexander Gaiger, Klaus Geissler, Hildegard T. Greinix, Wolfgang Gstoettner, Marcus Hacker, Bernd Lorenz Hartmann, Alexander W. Hauswirth, Tim Heinemann, Daniel Heintel, Mir Alireza Hoda, Georg Hopfinger, Ulrich Jaeger, Lukas Kazianka, Lukas Kenner, Barbara Kiesewetter, Nikolaus Krall, Gerhard Krajnik, Stefan Kubicek, Trang Le, Simone Lubowitzki, Marius E. Mayerhoefer, Elisabeth Menschel, Olaf Merkel, Katsuhiro Miura, Leonhard Muellauer, Peter Neumeister, Thomas Noesslinger, Katharina Ocko, Leopold Oehler, Michael Panny, Alexander Pichler, Edit Porpaczy, Gerald W. Prager, Markus Raderer, Robin Ristl, Reinhard Ruckser, Julius Salamon, Ana-Iris Schiefer, Ann-Sofie Schmolke, Ilse Schwarzinger, Edgar Selzer, Christian Sillaber, Cathrin Skrabs, Wolfgang R. Sperr, Ismet Srndic, Renate Thalhammer, Peter Valent, Emiel van der Kouwe, Katrina Vanura, Stefan Vogt, Cora Waldstein, Dominik Wolf, Christoph C. Zielinski, Niklas Zojer, Ingrid Simonitsch-Klupp, Giulio Superti-Furga, Berend Snijder, Philipp B. Staber

Summary: Personalized medicine using functional assays can be clinically feasible and effective in providing treatment guidance for patients with aggressive hematologic cancers, resulting in enhanced progression-free survival and exceptional responses lasting longer than expected for some patients.

CANCER DISCOVERY (2022)

Article Critical Care Medicine

Add-On Prostaglandin E1 in Venovenous Extracorporeal Membrane Oxygenation

Nina Buchtele, Christian Schoergenhofer, Michael Schwameis, Bernd Jilma, Peter Schellongowski, Harald Herkner, Katharina Riss, Monika Schmid, Alexander Hermann, Oliver Robak, Bernhard Nagler, Ludwig Traby, Andja Bojic, Thomas Staudinger

Summary: This study investigated the safety and efficacy of PGE(1) in adults receiving venovenous extracorporeal membrane oxygenation (ECMO). The results showed that PGE(1) can reduce thromboembolic events and clinically overt bleeding events, as well as prolong the time without bleeding and thromboembolism.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)

Article Medicine, General & Internal

Subcutaneous Enoxaparin for Systemic Anticoagulation of COVID-19 Patients During Extracorporeal Life Support

Marion Wiegele, Daniel Laxar, Eva Schaden, Andreas Baierl, Mathias Maleczek, Paul Knoebl, Martina Hermann, Alexander Hermann, Christian Zauner, Johannes Gratz

Summary: This study retrospectively analyzed the use of subcutaneous enoxaparin for systemic anticoagulation in COVID-19 patients undergoing extracorporeal membrane oxygenation. The results showed that enoxaparin was associated with lower rates of thromboembolic and hemorrhagic events compared to unfractionated heparin. The findings suggest that subcutaneous enoxaparin may be a successful alternative for anticoagulation in these patients.

FRONTIERS IN MEDICINE (2022)

Article Hematology

Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 study

Olga Oleshko, Sonja Werwitzke, Annika Klingberg, Torsten Witte, Hermann Eichler, Robert Klamroth, Katharina Holstein, Christina Hart, Christian Pfrepper, Paul Knoebl, Richard Greil, Peter Neumeister, Birgit M. Reipert, Andreas Tiede

Summary: The root cause of autoantibody formation against FVIII in AHA is unclear. A diverse pattern of autoantibodies is associated with AHA, suggesting a more general breakdown of immune tolerance might be involved in its pathology.

BLOOD ADVANCES (2023)

Article Hematology

Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study

Marie Scully, Javier de la Rubia, Katerina Pavenski, Ara Metjian, Paul Knoebl, Flora Peyvandi, Spero Cataland, Paul Coppo, Johanna A. Kremer Hovinga, Jessica Minkue Mi Edou, Rui De Passos Sousa, Filip Callewaert, Sriya Gunawardena, Julie Lin

Summary: Long-term follow-up supports the safety and efficacy of caplacizumab for iTTP and its repeated use for recurrences.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)

Article Hematology

N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia

Irene Graf, Georg Greiner, Rodrig Marculescu, Karoline Gleixner, Susanne Herndlhofer, Gabriele Stefanzl, Paul Knoebl, Ulrich Jaeger, Alexander Hauswirth, Ilse Schwarzinger, Renate Thalhammer, Michael Kundi, Gregor Hoermann, Gerlinde Mitterbauer-Hohendanner, Peter Valent, Wolfgang R. Sperr

Summary: Patient-related factors, including N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, age, and the 2009 European LeukemiaNet (ELN-2009) classification, independently predict outcomes in acute myeloid leukemia (AML) patients receiving induction chemotherapy. Elevated NT-proBNP levels are associated with increased risk of induction failure, early death, and reduced overall survival (OS) in AML patients. These findings highlight the importance of considering cardiac disorders and NT-proBNP as prognostic factors in AML treatment.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Editorial Material Hematology

Safer steps on a narrow path

Paul Knoebl

BLOOD (2022)

Article Pharmacology & Pharmacy

Management of acquired haemophilia A in severe Covid-19: Haemostatic bridging with emicizumab to keep the balance between bleeding and thrombosis

Georg Gelbenegger, Ludwig Traby, Nina Rahimi, Paul Knoebl

Summary: This study presents a treatment approach for a 75-year-old male with severe Covid-19, acquired haemophilia A, and severe muscle bleeding. The treatment includes haemostatic therapy and immunosuppression. Different reagents are used to measure the activity of coagulation factor VIII, and recombinant human activated FVII and emicizumab are administered for haemostatic control. Steroids and rituximab are used for immunosuppression. The treatment is effective with no thromboembolic events.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2023)

Article Cardiac & Cardiovascular Systems

Secondary calciprotein particle size is associated with patient mortality in peripheral artery disease

Marija Bojic, Daniel Cejka, Bernhard Bielesz, Gerit-Holger Schernthaner, Clemens Hoebaus

Summary: This study investigates the association between the size of secondary calciprotein particles (CPP-II) and mortality in peripheral artery disease (PAD) patients. The results suggest that larger CPP-II size is significantly associated with all-cause and cardiovascular mortality in this patient population, indicating its potential as a new feasible biomarker for the presence of media sclerosis.

ATHEROSCLEROSIS (2023)

Article Nutrition & Dietetics

Inadequate Energy Delivery Is Frequent among COVID-19 Patients Requiring ECMO Support and Associated with Increased ICU Mortality

Mathias Schneeweiss-Gleixner, Bernhard Scheiner, Georg Semmler, Mathias Maleczek, Daniel Laxar, Marlene Hintersteininger, Martina Hermann, Alexander Hermann, Nina Buchtele, Eva Schaden, Thomas Staudinger, Christian Zauner

Summary: This study retrospectively analyzed the nutrition support in COVID-19 patients requiring ECMO therapy and found that patients who achieved nutrition goals had higher ICU survival rate. Thus, providing adequate nutritional support is a major priority in the treatment of COVID-19 patients requiring ECMO support.

NUTRIENTS (2023)

Article Hematology

Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study

Andreas Tiede, Christina Hart, Paul Knoebl, Richard Greil, Johannes Oldenburg, Ulrich J. Sachs, Wolfgang Miesbach, Christian Pfrepper, Karolin Trautmann-Grill, Katharina Holstein, Jan Pilch, Patrick Moehnle, Christoph Schindler, Carmen Weigt, Dorothea Schipp, Marcus May, Christiane Dobbelstein, Fabius J. Pelzer, Sonja Werwitzke, Robert Klamroth

Summary: The study investigated the use of emicizumab, a factor VIIIa mimetic antibody, in preventing bleeding and deferring immunosuppression in patients with acquired haemophilia A. The results showed that emicizumab was effective in preventing bleeding and allowed patients to defer immunosuppression during the treatment period, indicating potential treatment advantages.

LANCET HAEMATOLOGY (2023)

Article Hematology

Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura

Linus A. Voelker, Jessica Kaufeld, Gesa Balduin, Lena Merkel, Lucas Kuehne, Dennis A. Eichenauer, Thomas Osterholt, Holger Haegele, Martin Kann, Franziska Grundmann, Benedikt Kolbrink, Kevin Schulte, Anja Gaeckler, Andreas Kribben, Kristina Boss, Sebastian A. Potthoff, Lars C. Rump, Tilman Schmidt, Anja S. Muehlfeld, Karsten Schulmann, Matthias Hermann, Jens Gaedeke, Kristin Sauerland, Joern Bramstedt, Ulrich P. Hinkel, Wolfgang Miesbach, Frederic Bauer, Timm H. Westhoff, Heike Bruck, Veronika Buxhofer-Ausch, Tobias J. Mueller, Ralph Wendt, Ana Harth, Adrian Schreiber, Evelyn Seelow, Markus Toelle, Christopher Gohlisch, Markus Bieringer, Gesa Geuther, Wolfram J. Jabs, Michael Fischereder, Anke von Bergwelt-Baildon, Ulf Schoenermarck, Paul Knoebl, Jan Menne, Paul T. Brinkkoetter

Summary: This study retrospectively reviewed the use of von Willebrand factor-directed nanobody caplacizumab in the treatment of immune thrombotic thrombocytopenic purpura (iTTP). The results showed that caplacizumab was efficacious when used in the early stages of iTTP and until partial ADAMTS13-activity remission, leading to a reduction in mortality and hospital stay.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2023)

Article Hematology

Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group

Christian Pfrepper, Robert Klamroth, Johannes Oldenburg, Katharina Holstein, Hermann Eichler, Christina Hart, Patrick Moehnle, Kristina Schilling, Karolin Trautmann-Grill, Mohammed Alrifai, Cihan Ay, Wolfgang Miesbach, Paul Knoebl, Andreas Tiede

Summary: This study provides clinical practice recommendations on the use of emicizumab in acquired hemophilia A (AHA). The results show that emicizumab is effective for bleed prophylaxis and should be considered from the time of diagnosis. A fast-loading regimen of 6 mg/kg on day 1 and 3 mg/kg on day 2 should be used if rapid bleeding prophylaxis is required. Maintenance doses of 1.5 mg/kg once weekly should be given. Immunosuppression should be offered to eligible patients on emicizumab. Emicizumab should be discontinued when remission of AHA is achieved.

HAMOSTASEOLOGIE (2023)

Article Oncology

Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine

Tim Heinemann, Christoph Kornauth, Yannik Severin, Gregory Vladimer, Tea Pemovska, Emir Hadzijusufovic, Hermine Agis, Maria-Theresa Krauth, Wolfgang R. Sperr, Peter Valent, Ulrich Jager, Ingrid Simonitsch-Klupp, Giulio Superti-Furga, Philipp B. Staber, Berend Snijder

Summary: This study demonstrates the use of deep learning in identifying malignant and nonmalignant cells by morphology, improving drug screening for patients with hematologic cancers. The findings highlight the potential of deep learning-enhanced ex vivo drug screening in personalized treatment options.

BLOOD CANCER DISCOVERY (2022)

No Data Available